The device-aided intrajejunal delivery of levodopa–entacapone–carbidopa intestinal gel the treatment of Parkinson’s disease: overview of efficacy and safety

Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson's disease (PD) whose symptoms can no longer be effectively managed with oral or transdermal therapy. Intrajejunal infusion of levodopa-carbidopa intestinal gel (LCIG), d...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Expert review of medical devices Ročník 22; číslo 6; s. 533 - 544
Hlavní autoři:	Popławska-Domaszewicz, Karolina, Metta, Vinod, Odin, Per, Chaudhuri, K Ray
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 03.06.2025
Témata:	Antiparkinson Agents - administration & dosage Antiparkinson Agents - therapeutic use Carbidopa - administration & dosage Carbidopa - adverse effects Carbidopa - therapeutic use Catechols - administration & dosage Catechols - adverse effects Catechols - therapeutic use Clinical Medicine Drug Combinations Drug Delivery Systems - instrumentation Gels Humans Jejunum Klinisk medicin Levodopa - administration & dosage Levodopa - adverse effects Levodopa - therapeutic use Medical and Health Sciences Medicin och hälsovetenskap Neurologi Neurology Nitriles - administration & dosage Nitriles - adverse effects Nitriles - therapeutic use Parkinson Disease - drug therapy Treatment Outcome advanced parkinson’s disease infusion pump Device-aided therapy LECIGON medical device levodopa–carbidopa–entacapone
ISSN:	1743-4440, 1745-2422, 1745-2422
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!